New
HealthMore in Health→
EVAOLD trial bolsters routine invasive care for older NSTEMI patients
Key Takeaways
- The EVAOLD trial, presented at ESC Congress 2026, found that routine invasive management should not be replaced with a selective, stress-test-guided approach in older NSTEMI patients.
- The randomized trial enrolled patients aged 80 and older with NSTEMI and planned to test noninferiority of a stress-imaging-first strategy against routine invasive care.
- At the first interim analysis, after 587 patients, the trial was stopped for futility because the conditional chance of demonstrating noninferiority was low.
- The study's principal investigator, Professor Gilles Barone-Rochette, highlighted that benefit-risk uncertainty and complication risk had prompted the hypothesis that stress testing could act as a gatekeeper.
DE
DT Editorial Team··via medicalxpress.com